skip to Global Navigation Bar skip to main content

homeHome > About Us > Press Release > News


News Content
FDA resumes review of Daewoong Pharmaceutical’s Nabota
Date 2018-08-30 Hit 1628
News List
Prev Nabota received approval from Health Canada
Next Daewoong Pharmaceutical’s ‘NABOTA’ becomes the first Korea-made Botulinum Toxin to obtain US FDA approval